Horizon Discovery’s Bioproduction Cell Line Used as Part of a Successful Drug (IND) Filing
Industry adoption of Horizon’s CHO K1 GS knockout cell line has provided the Group with a strong source of repeatable revenue that has accelerated in recent months, with over 20 full commercial licenses in place and a strong pipeline of new licenses pending. These licenses have been secured as a result of Horizon’s unrivalled combination of high performance, transparent cell line history, and disruptive licensing terms. Now, as an important part of a successful IND filing by a licensee, Horizon’s Bioproduction cell line has been proven as a high-value platform upon which regulatory submissions can be based.
Horizon licenses its CHO K1 cell line broadly across the industry including to pharmaceutical, biotechnology, and biosimilar companies, as well as to Contract Manufacturing Organizations (CMO). By adopting this approach, Horizon intends to demonstrate its global leadership, empowering organizations of all sizes by providing access to the best biotherapeutic manufacturing technology available, driving efficiencies so that they, and ultimately patients, benefit.
Richard Vellacott, Interim CEO and CFO, Horizon Discovery, commented: "Next-generation biotherapeutics require next-generation manufacturing platforms. We are pleased that our highly specialized gene-edited cell line for bioproduction is not only being widely adopted by customers of all sizes but has now also been validated as a highly effective platform for regulatory submissions. Today’s announcement enables Horizon to access a wider customer base and represents a significant milestone in our goal of harnessing the power of the cell to empower customers across the life sciences.”
Zyme Communications (Trade and Regional Media)
Tel: +44 (0)7787 502 947
Source: Horizon Discovery